Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

Novo Nordisk (NVO) has launched its weight-loss drug Wegovy in Thailand, Reuters reported on Monday, citing an executive of ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Novo Nordisk (NVO) closed the latest trading day at $62.62, indicating a +0.87% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.06%. At the same time, the Dow ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

By Sukriti Gupta and Medha Singh (Reuters) -European shares fell on Tuesday, dragged down by heavyweight Novo Nordisk, while ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...